Leerink Partners reiterated a Market Perform rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and cut the price target to $11.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Ironwood Pharmaceuticals (IRWD) Costs Increase to Offset Revenue Upside - WedbushFebruary 19, 2016 9:51 AM Mizuho Securities Reiterates Buy Following Ironwood Pharma's (IRWD) Strong 4Q Results February 19, 2016 9:30 AM BTIG Sees Opportunity in Ironwood Pharma (IRWD) Weakness; Affirms at 'Buy'February 19, 2016 7:50 AM Ironwood Pharma (IRWD) Tops Q4 EPS by 7cFebruary 18, 2016 4:07 PM Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor UpdateFebruary 18, 2016 4:05 PM Ironwood Pharma (IRWD) to Initiate Phase Ib Study of IW-1701 Following Positive Top-Line Phase Ia DataFebruary 18, 2016 8:23 AM Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701February 18, 2016 8:00 AM Ironwood Pharmaceuticals to Present at 2016 RBC Capital Markets Global Healthcare ConferenceFebruary 17, 2016 4:01 PM Trading Radar for 2/18: Wal-mart (WMT), Cabela's (CAB), Nordstrom (JWN), Leidos (LDOS), SodaStream (SODA) ReportFebruary 17, 2016 3:18 PM